Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGA trial of nivolumab + trastuzumab with ipilimumab or FOLFOX in untreated HER2-positive esophagogastric adenocarcinoma
2017-000624-10Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, trastuzumab, ipilimumab, oxaliplatin, fluorouracil and 1 more in gastroesophageal junction adenocarcinoma and gastric cancer (GC) (2 arms), sponsored by AIO-Studien. Primary endpoints: Overall survival and 12-month overall survival milestone rate. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2017-000624-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000624-10.